Wednesday, 13th November Clinical Oncology Society of Australia Annual Scientific Meeting 2024

This symposium will highlight the latest research from the COSA Nutrition and Exercise Groups – spanning the launch of the COSA Cancer-related malnutrition and sarcopenia position statement: Implementation Toolkit, the mapping of nutrition services in Australian acute health services providing cancer treatment and the latest on investigating the value of implementation of the COSA Position Statement on Exercise in Cancer Care.

The audience will walk away with insights from the latest nutrition and exercise research and how to elevate multidisciplinary care in practice to optimise outcomes for people with cancer. An interactive panel discussion with all speakers and questions from the audience will conclude the session.

Speakers and topics:

• Jane Stewart - Launch of the COSA Cancer-related malnutrition and sarcopenia position statement: Implementation Toolkit

• Dr Emily Jeffery - Survey of nutrition service provision in Australian acute cancer settings

• Dr Kim Edmunds - COSA Exercise guidelines: What is the Value of Implementation?

This session will include interactive Q&A with all speakers.

This breakfast session is sponsored by COSA, and delivered by the COSA Nutrition and Exercise and Cancer Groups

Welcome by COSA President
Welcome to Country by local Indigenous group

- Danielle Rodin - Global overview of Equity: the radiation oncology perspective
- Robin Zon - Global overview of Access: what is ASCO doing to reduce disparities
- TBC - National advocacy agenda setting to improve the lives of Aboriginal and Torres Strait Islander peoples with cancer

• Global overview of Equity: the radiation oncology perspective - Danielle Rodin
• Global overview of Access: what is ASCO doing to reduce disparities - Robin Zon
• National advocacy agenda setting to improve the lives of Aboriginal and Torres Strait Islander peoples with cancer - Haylene Grogan

• Telehealth in Oncology: ASCO Standards and Practice Recommendations - Robin Zon
• Teletrials – where are we up to? - Amy Ives
• Teletrials – how are they working for regional sites? - Hayden Christie
• Telehealth: Bridging the gaps in first nations cancer care. - Shivanshan Pathmanathan

Followed by panel discussion and Q&A

Chair: Leonie Young

• Good, bad, short, long, or the space in between: Discussing quality and quantity of life. - Michael S Krasovitsky
• Navigating difficult interactions with family and friend carers - Rebekah Laidsaar-Powell
• Raising the bar: Discussions about alcohol after a cancer diagnosis - Maree Grier
• Cancer is awkward - dealing with uncomfortable conversations. - Nicola Du Thaler

Followed by panel discussion and Q&A

Chair: Bodga Koczwara

• Multi-morbidity and inferior outcomes in cancer survivors - Susan Dent
• Multimorbidity in Aboriginal and Torres Strait Islander people - Abbey Diaz
• Multimorbidity in cancer survivors – using big data to improve practice - Huah Shin Ng
• Multimorbidity – the core business of primary care. - Christelle Greeff

Followed by panel discussion and Q&A

• Patterns of medication use following breast cancer diagnosis: an Australian population-based study - Huah Shin Ng
• Understanding how the impact of cancer varies by geographic location: Insights from the new Australian Cancer Atlas 2.0 - Peter D Baade
• The association between cardiorespiratory fitness and breast, colon, and lung cancer incidence and mortality in 166 124 Swedish women - Kate A Bolam
• Timeliness and Guideline-Concordant Treatment in Small-Cell Lung Cancer: Factors Influencing Outcomes in Victoria - Sanuki Tissera
• Receipt and response to neoadjuvant chemotherapy treatment and survival outcomes in triple-negative breast cancer in Queensland: a retrospective population-based cohort - Larissa Vaz-Goncalves
• Risk Factors of Colorectal Cancer after a Colonoscopy: A Retrospective Cohort Study of Australian Patients Aged 75 and Older - Molla M Wassie

• We can see the future of cancer inequity - can we change it? - Paul B Grogan
• Unlocking Diversity: A Prospective Study of Ancestry, English Proficiency, Culturally and Linguistically Diverse Participation in NSW Phase 1 Cancer Trials - Chien Ng
• When good intentions are not enough: The development of the Equity ProcEss frameworK (EPEK) to promote equity in cancer - Brighid Scanlon
• Rural cancer survivors’ perceived delays in seeking medical attention, diagnosis, and treatment: A qualitative study - Alyssa Taglieri-Sclocchi
• Development of an Optimal Care Pathway for people with cancer living in rural and remote Australia - Anna Ugalde
• Efficacy of an online mindfulness program (MindOnLine) to reduce fear of recurrence in people living with and beyond, breast, prostate or colorectal cancer: a randomized controlled trial - Natalie Winter

COSA Survivorship Group meeting                             Rooms 5 & 6

 COSA Global Oncology Group meeting                       Rooms 7 & 8

COSA NETs Group meeting                                         Room 9

• Identifying and Responding to Domestic Violence Within a Healthcare Setting - Grace Hallewell
• Disability care and cancer care - we can do both - Shona Edwards
• Cancer Care in Custody - Genni Newnham
• Incorporating class and culture awareness into routine cancer care - strategies to promote equity in Australian cancer systems - Abhijit PAL

• Clinicians’ and patients’ knowledge, understanding and communication related to biomarkers in cancer care: a systematic review - Rehana Abdus Salam
• Clinical and pathological significance of cancer stem cells markers - Reem ALHulais
• Gamma-interferon-induced lysosomal thiol reductase promotes metastasis via stabilizing cofilin in prostate cancer - Gang Chen
• Next-Generation Cancer Therapies: Novel Small Molecule Inhibitors Targeting Cancer Stem Cells   - Fathelrahman Gameel
• Prevalence and co-mutation status of MTAP deletions - Samuel Harris
• Discovery of DYRK1A Inhibitors as Potential Treatment of Pancreatic Ductal Adenocarcinoma (PDAC) - Hsing-Pang Hsieh
• Novel Approach to Anti-tumor and Anti-SARS-COV-2 Drugs by Modulating Sialylation of N-Glycans - Wen-Shan Li
• Improving oral health of cancer patients: dentists’ perspectives - Sheau Ling Low
• Hypermethylated HIST1H4F as a Biomarker for screening Endometrial Carcinoma in Endometrial Brush Samples - Qi Lu
•  Evaluating the clinical utility of circulating cell-free DNA in endometrial cancer: A systematic scoping review - Eliza Macdonald
• Evaluation of Survivorship Care Plans at Northeast Health Wangaratta - Sian Wright
• Cost impact of chemotherapy dose banding: a pilot analysis of six commonly prescribed drugs - Michelle Rantucci
• Identifying molecular key players in prostate cancer cell migration and metastasis - Joan Roehl
• Exploring Intimacy and Sexual Quality of Life in Prostate Cancer: A Qualitative Study - Karina Rune
• Clinical staff satisfaction and experience with implementation of a multidisciplinary model of community palliative care: A mixed methods study  - Jessica Scaife
• A general practice toolkit to promote physical activity among people living with cancer - Kylie Vuong
• Exploring clinical trials awareness, information access and participation amongst Australians with ovarian cancer: a qualitative study - Natalie Williams
• Optimising gynaecological cancer nursing care: Nurse and consumer perceptions on the development of a guidance resource - Natalie Williams
• Epithelial cell adhesion molecule induces induces Wnt receptor transcription to promote colorectal cancer progression - Han-Chung Wu
• Mechanism and predictive model for paclitaxel and immunotherapeutic responses in ovarian cancer - Guoxiong Xu
• The synergic effect of PD1 inhibitor and FLASH radiotherapy in a syngeneic mouse model of lung cancer: preliminary results - Tosol Yu
• Bundling and patient navigation in early-stage breast cancer care – Patient reported interim findings of a 100 patient pilot study - Yvonne Zissiadis
• Opioid analgesics for people living with cancer - Christina Abdel Shaheed
• TRIAL IN PROGRESS: An open label phase I multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP - Francis Hinds
• Time Course of Adverse Events in Primary Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab Plus Chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial - Ashish Banerjee
• Post-Progression Survival Outcomes in Patients with Primary Advanced or Recurrent Endometrial Cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial Who Received Follow-up Immunotherapy - Ashish Banerjee
• Influence of p16 (HPV) Status on Head and Neck Squamous Cell Carcinoma Behaviour: A Retrospective Study - Emily Frances Brown
• Nutritional needs in patients with recurrent/metastatic Head & Neck Cancer (R/M HNSCC) receiving immune checkpoint inhibitors (ICI) - Teresa Brown
• Investigating the impact of skull base surgery on nutrition and swallowing outcomes - Teresa Brown
• A pelvic floor rehabilitation program for patients with low anterior resection syndrome after sphincter-preserving surgery for colorectal cancer: a feasibility study  - Kin Yin Carol Chan
• An audit of medical oncology patients who died within 30 days of systemic anticancer therapy   - Millicent Chapman
• Socioeconomic status and its impact on Stage at Diagnosis and Survival in Women with Breast Cancer in Korea: A K-CURE Study - Sun Hyung Choi
• An individualised bone-targeted exercise intervention for people with multiple myeloma: Study protocol of the MyeEx-Impact randomised controlled trial - Jamie Chong
• What is the ideal dosing regimen for standardised ginger as an adjuvant CINV intervention in adults and children - Megan Crichton
• Understanding the Individualisation of Exercise Prescription for People with Cancer: A Systematic Review - Brent Cunningham
• Diet quality is not associated with malnutrition, low muscle mass and sarcopenia during lung cancer treatment - Annie R Curtis
• Colorectal cancer survivorship in a cohort of Sri Lankan patients; the time to widen focus from the care of acute patients to long-term survivors - Raeed Deen
• Exploring the long-term experiences, needs and coping strategies of people living with haematological cancer - Haryana Dhillon
• Establishing an Internal Audit Program for Investigator Initiated & Collaborative Group Trials - Joel Ernest
• Protocol investigator teams – where are the nurses? A retrospective audit of collaborative clinical trial protocols - Rayan Saleh Moussa
• A retrospective analysis of gemcitabine induced haemolytic uraemic syndrome in a single centre in Western Australia - Shane Fitzgerald
• Prospective review of Pneumocystis Jiroveci pneumonia occurrence in the treatment of solid tumours in a single centre in Western Australia - Shane Fitzgerald
• Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the Phase II VISION trial - Stephanie Gasking
• Expanding the scope of transoral robotic surgery: is it useful as a salvage technique in head and neck cancers? - Sahil Goel
• Prognostic value of systemic inflammation response index (SIRI) in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysis - Xiaobin Gu
• Longer-term Safety and Efficacy of Selinexor Maintenance Therapy for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: Follow-up Subgroup Analysis of the ENGOT-EN5/GOG-3055/SIENDO Study - Paul Haluska
• Energy expenditure in head and neck cancer: a systematic literature review - Lauren Hanna
• Tumour Heterogeneity and Discordance of ER, PR and HER2 Receptors between Primary and Recurrent Breast Cancer: A Systematic Literature Review - Archana Haria
• Early cessation of adjuvant chemotherapy in WA patients with resected lung cancer - determinants of early cessation and impact on outcomes - Teng Yik Hoo
• Skin adverse events of anti-cancer treatments: an examination of drug-adverse events associations - Kiarash Khosrotehrani
• Holistic Model of Leukaemia Survivorship Care: derived from a qualitative exploration of leukaemia survivorship - Shaun Kirsten
• Pattern of access to genomically-linked therapies associated with pan-cancer biomarkers in advanced cancer patients: Insights from the Australian Molecular Screening and Therapeutics (MoST) Program - Christine E Napier
• The use of durvalumab following definitive chemo-radiotherapy in unresectable stage III non-small-cell lung cancer – an experience of the Northern Adelaide Cancer Centre - Rama Devi Penumarty
• Peripheral neuropathy and hypersensitivity reactions from paclitaxel chemotherapy in patients with early breast cancer, experience in South-Western Sydney - Thi Thuy Duong Pham
• Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC - Aarohan Pruthi
• Intracranial Outcomes of 1L Selpercatinib in Advanced RET Fusion-positive (RET+) NSCLC: LIBRETTO-431 Study - Aarohan Pruthi
• Health-related Quality of Life (HRQoL) and Symptoms in LIBRETTO-431 Patients with RET Fusion-positive Advanced Non-Small-Cell Lung Cancer (NSCLC) - Aarohan Pruthi
• Efficacy of Selpercatinib by RET Fusion Partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 Trials - Aarohan Pruthi
• Dose Adjustments and Exposure-Response Associated With Selpercatinib in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - Aarohan Pruthi
• Upper-body function predicts breast cancer-related lymphoedema: Results from a prospective, population-based cohort study - Hildegard Reul-Hirche
• Service utilisation of the first hospital-based psychological service for carers of people with cancer - Ella Sexton
• Comparing the Outcomes of Frail Acute Myeloid Leukaemia Patients Undergoing Systemic Therapy to their Fitter Counterparts - Aaron Sia
• Development of a Self-Reported Frailty Index - the SELFI - Aaron Din How Sia
• Feasibility of a structured telehealth intervention study ‘Lifestyle intervention (Exercise And Diet) for early-stage Breast Cancer Survivors (LEAD-4-BCS) undergoing neo-/adjuvant chemotherapy - Sim Yee (Cindy) Tan
• Retrospective evaluation of non-small cell lung cancer management in Western NSW Local Health District (Dubbo sector) - Emily Turnbull
• A Randomised Controlled Trial: Evaluating Whether a Cognitive-Behavioural Internet-Delivered Intervention Targeting Emotion Regulation Improves Health-Related Quality of Life in Cancer Survivors - Rebecca Wallace
• Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study - Yong-Shuai Wang
• Comparable dapsone dosing for PJP prophylaxis in cancer patients: breaking down guidelines and building safer alternatives - Michael Whordley
• Pro-health: co-design of a remotely delivered nutrition and exercise web-program for men with prostate cancer on androgen deprivation therapy  - Brenton Baguley
• Factors associated with bowel cancer screening participation of First Nations peoples accessing home care services in New South Wales, Australia - Tsegaw Amare Baykeda
• Design Principles for the Development of Equitable Digital Health Technologies to support people with Pancreatic Cancer   - Kara Burns
• Co-Designing Resource-Appropriate Breast Cancer Guidelines for the Solomon Islands: A Collaborative Approach with Local and International Experts - Lauren Canning
• Queensland state-wide patterns and access to EGFR mutation testing for metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) from 2014-2021 - Bryan A Chan
• Bridging the Gap: Understanding the Sociodemographic Disparities in Access to Early Prostate Cancer Detection in Australia - Rani R Chand
• Delays in Commencing Radiotherapy and Systemic Therapy for Gynaecological Cancer Patients in Regional New South Wales - Angela Chen
• How does the health system support advance care planning with culturally and linguistically diverse communities? A document analysis   - Upma Chitkara
• Compassionate Access Drug Use for Oncology Treatment: Single Institution Retrospective Audit 2017-2024   - Yun San Chong
• The receipt of surgery versus radiation therapy by Aboriginal and Torres Strait Islander people diagnosed with prostate cancer in NSW - Julieann Coombes
• Health technology assessment decision-makers evaluating precision medicine technologies: a qualitative interview study in three countries - Tess Cooper
• Longitudinal Multidisciplinary Intervention (LMI) During the Entire Disease Trajectory Improves Long-Term Outcomes in Younger Patients with Metastatic Colorectal Cancer: A Retrospective Analysis in the Australian Context - Prasad Cooray
• A Call for National Young Onset Colorectal Cancer Roadmap - Prasad Cooray
• Pregnancy-Associated Colorectal Cancer in Australia: A Consumer-Initiated Qualitative Case Series - Prasad Cooray
•  Health System Interactions Among Regional, Rural, and Remote Cancer Carers in Australia: preliminary results from a national survey   - Stephanie P Cowdery
• How do cancer clinical trials include people from diverse genders and sexual orientations? - Haryana M Dhillon
• Equity of Head and Neck Cancer: Older Age And The Importance Of Social Networks In Cancer Patients Living In Rural And Regional Victoria When Seeking Treatment - Henna HE Eqbal
• Challenges and Preparedness for Utilising the Teletrial Model: Qualitative Evaluation from A Primary Site Perspective - Joel Ernest
• Transforming access to cancer care: A patient centered, national accommodation directory   - Katherine Lane
• Enhancing Prostate Cancer Awareness Through Targeted Community Campaigns in a High-Risk Victorian Region  - Warren Flatt
• CASEMED CAncer Patients with pre-existing SEvere MEntal Disorders Development and pilot test of a collaborative care model - Louise Elkjær Fløe
• “Is it because I'm getting older or is it because I've got cancer?” – Experiences and perceptions of cancer care for an older adult with cancer - Sharon He
• The Nationally Harmonised Teletrial Supervision Plan - Nadine Herren
• On our way to creating a networked clinical trial system: Lessons learnt from the last 2 years - Kaye Hewson
• Collaborative, patient guided approach to a first-in-human study for advanced cancer - Francis Hinds
• Blind spots in the hospital: an absence of CALD data - Marlies Iserlohe
• Reducing the burden on rural cancer patients and their families travelling for treatment: A forecast social return on investment analysis of the MEAL project - Elizabeth (Lizzy) Johnston
• An international comparison of the eligibility and reach of lung cancer screening: implications for Australia’s national lung cancer screening program - Hannah Jongebloed
• Impact of Age on Time to Chemotherapy Initiation in Breast Cancer Patients: A Comparative Analysis of <50 vs. >50 Years Old - Sachin Joshi
• Enhancing Health Equity for All: The Australian Teletrial Program - Priyakshi Kalita-de Croft
• What Services Are Available for Culturally and Linguistically Diverse (CALD) Patients in the Survivorship Setting? An Australian Study - Lawrence Kasherman
• The Australian Cancer Plan: Improving equitable access to optimal care - David Meredyth
• Predictors of employment outcomes in cancer survivors: a systematic scoping review - Emma Kemp
• Enabling access to clinical trials for regional patients with cancer, an operational perspective from The Kinghorn Cancer Centre, St Vincent’s Hospital - Robert Kent
• How does social isolation and socioeconomic status affect cancer trial participation? Results from PEARLER, prospective dataset of patients entering early phase trials in NSW  - Kevin Lin
• A new Cancer Nurse Inake Coordinator provides pateint focused early navigation support for solid tumours - Melissa Loorham
• Empowering Diversity: Mobile App Improves Accessibility and Training for Multilingual Radiation Therapy Patients in Breath-Hold Techniques - Toby Lowe
• Achieving Equitable Access to Optimal Cancer Outcomes for People with Disability - Clare N Lynex
• VICS Optimal Care Summits protocol - describing our methods for determining unwarranted variations in cancer care - Ashley Macleod
• Examining the experience of culturally and linguistically diverse cancer patients in Victoria using the 2023 Cancer Patient Experience Survey data  - Ashley Macleod
• An evaluation of the cancer experience of Aboriginal and Torres Strait Islander cancer patients in Victoria using the 2023 Cancer Patient Experience Survey data  - Ashley Macleod
• A regulatory perspective on the setup of decentralised clinical trials - Chloe Martin
• Delays to Post-Operative Radiation Therapy for Patients with Head and Neck Squamous Cell Carcinoma: A Mixed-Methods Analysis of Health Worker Perspectives - Ravi Marwah
• Enhancing the wellbeing of refugees living with advanced life-limiting illness, their families and carers in high-income resettlement countries: a qualitative systematic review - Heidi Merrington
• Digital health technology use among people diagnosed with cancer aged 55 years and over: Findings from the 45 and Up Study - David Mizrahi
• Provision of cancer systems by cancer services for culturally and linguistically diverse patients - Meng Tuck Mok
• Understanding the provision of palliative care for people experiencing homelessness in Victoria  - Jumaien Momen
• The feasibility of nurse-led telephone follow-up for breast cancer patients in India: Perspectives from healthcare professionals - Ambili AN Nair
• Achieving equity for all cancer patients - a prospective study of representation of LGBTQIA+ patients on early phase cancer clinical trials: results from a PEARLER sub-study - Rebecca H Nguyen
• Experiences of Arabic speaking patients in Australian cancer care and views on enablers of clinical trial participation - findings from a Consumer Workshop in NSW - Abhijit Pal
• Measuring the cost of informal cancer caregiving: development of a co-designed economic assessment tool - Cara M Platts
• Understanding unwarranted variations in care for Victorian oesophagogastric cancer patients: a comparative analysis between 2012-2016 and 2017-2021 - Helena Rodi
• Identification of unwarranted variations, causes and improvement priorities in Victorian oesophagogastric cancer care: a mixed-methods analysis  - Helena Rodi
• The national landscape of needs-analysis assessment to promote equitable exercise and diet referrals in oncology practice: The NEEDS study - Grace L Rose
• Opportunities and future directions to create equitable clinical trial system in Australia - Sabe Sabesan
• Perspectives of healthcare professionals and researchers on barriers and enablers of cancer clinical trial participation among Arabic-speaking Australians   - Rayan Saleh Moussa
• Examining Prognostic Disparities between Regional and Metropolitan Lung Cancer Patients: A Registry based study - Evangeline Samuel
• Co-designing for implementation: A patient-focused clinical trials navigation tool - Kate Saw
• Equity in Action: A Strategic Approach to Financial Toxicity in Victoria - Beth Scholes
• Equitable access to support groups for people with metastatic cancer: Do we have the evidence to support their implementation? And if so, what factors are impacting on their adoption and roll-out across Australia? - Andrea L Smith
• Comparative Analysis of Biomarker Testing Rates and Treatment Patterns in NSCLC Patients: Australia vs. EU4+UK - Imogen Smith
• Patient navigation to improve ethnic minority cancer care in high income countries: A systematic review - Sandra Sonego
• Is patient age associated with treatment approach and survival outcomes in mucosal Head and Neck Squamous Cell Carcinoma? An Australian observational study - Puma Sundaresan
• Financial toxicity in regional and rural cancer patients: an Australian regional tertiary centre perspective - Jai Thompson
• Launch of the Co-Designed Equitable Cancer Outcomes across Rural and Remote Australia (ECORRA) Project - Anna Ugalde
• The impact of socioeconomic factors on incidence, mortality and morbidity of cardiovascular diseases in First Nations people with cancer: a systematic review  - Cassandra Vujovich-Dunn
• Evaluation of Cancer Clinical Trials Resources for Culturally and Linguistically Diverse (CALD) Communities - Verena S Wu
• Patterns of Bowel Cancer Diagnosis, Treatment and Outcomes in Relation to Culturally and Linguistically Diverse (CALD) Status in South Western Sydney Local Health District (SWSLHD) - Gui M Xiong
• Building regional clinical trial capacity and identifying unmet needs: 10-year audit of medical oncology clinic trials activated at the Sunshine Coast University Hospital and Health Service (SCHHS) - Betty Y Zhang
• Practical guidance for preparing and conducting hybrid focus groups and online interviews with consumers for cancer research  - Xanthia E Bourdaniotis
• Development of standardised digital onboarding pathways for cancer nurses - Olivia Cook
• Understanding the value of codesign: exploring participant experiences  - Vicki Durston
• An Evaluation of the acceptability and feasibility of the Alternative Access Model for bowel cancer screening among Mandarin speaking Chinese residents and Mandarin speaking health practices   - Lanxi Huang
• Reflective and Reflexive practices in tertiary healthcare students following cancer patient engagement: A scoping review - Daniel Johnstone
• Patient-Teachers: A cancer-consumer informed approach to using their stories in the education of healthcare students - Daniel Johnstone
• eviQ: Taking a BiTE® into Advanced Therapies - Aisling Kelly
• “Feeling unwell”: A Convergent Parallel Mixed Methods Survey of Rural Western Australians’ Perceptions of the Most Common Cancer Symptoms - Chloe M Maxwell-Smith
• Feasibility and value of a guided observation and reflection learning activity for medical students on clinical placement in Cancer Care - Erin Moth
• Knowledge, attitude and practice of young women (age 18-25) in Bangalore city with regards to self-breast examination - Swastik Pandita
• Malnutrition & sarcopenia in cancer: an eLearning program refresh - Hannah Ray
• Cancer Nursing: Not a Nursing Speciality in Papua New Guinea - Pauline M Rose
• Building capability: The experience of a delegate from Papua New Guinea with cancer pharmacist education delivered by Clinical Oncology Society of Australia’s Cancer Pharmacists Group - Marissa Ryan
• eviQ: increasing community pharmacy knowledge of anti-cancer medicines - Julia V Shingleton
• Implementing a pharmacist-led education initiative to improve rates of allergy recording in CHARM - Ashleigh Smith
• ANZGOG Community Engagement Program – how lived experience can shape future directions in gynaecological cancer research, advocacy and education - Aimhirgin Byrne
• From toxicity to recovery: A case report of a patient administered glucarpidase for methotrexate toxicity - Michael Whordley
• Data sharing in cancer research: A qualitative study exploring community members’ preferences - Susannah K Ayre
• Endocrine treatment uptake and time to treatment commencement among women with breast cancer: A Queensland population-based study - Habtamu Mellie Bizuayehu
• Heterogeneity in the distribution of cutaneous T-cell lymphomas (CTCL) across Australia mirrors dermatologist-density and highlights the unique challenges to diagnosis - Belinda Campbell
• Allergic disease and risk of multiple myeloma in EMMA: a case-control study - Simon Cheah
• Cancer incidence and survival statistics by histological type: A new approach for reporting cancer data in Australia by the Australian Institute of Health and Welfare   - Claire Cooke-Yarborough
• Cancer survivors’ health behaviour patterns and the relationship with health status and healthcare utilisation - Katia E Ferrar
• Menopausal hormone therapy use and future breast cancer risk in the Lifepool cohort: A comparative study adjusting for breast density - Saima Islam
• Assessment and stratification of cardiovascular disease risk in people diagnosed with breast cancer: A scoping review - Mihye Jeon
• Effects of perioperative exercise therapy (aerobic, resistance, pelvic floor, mind-body exercise, or mixed exercise (combined aerobic and resistance) on quality of life and adverse events in prostate cancer patients undergoing surgery: A PRISMA compliant systematic review and meta-analysis of randomised controlled trials (RCTs) - Nazib Khan
• Disparities in rare cancer incidence - comparative results from a population-based data analysis in Queensland - Ming ML Li
• Real-world usage patterns of palbociclib and associated patient characteristics in Australia: a retrospective analysis - Jessica Michie
• Advancements and Opportunities in Clinical Trial Data Sharing: A Review of CSR and IPD Accessibility for Oncology Trials - Natansh D Modi
• A Chat-tastrophe: Cross-sectional evaluation of customisable cancer GPTs accessible via OpenAI’s ChatGPT platform   - Natansh D. Modi
• Effect of metabolic factors on the risk of precancerous polyps among people undergoing surveillance colonoscopy: a systematic review and meta-analysis - Meseret Molla
• Patient-reported outcomes after prostate cancer treatment: Findings from the ACT Prostate Cancer Outcomes Registry (PCOR-ACT) - Michael Odutola
• Descriptive and Clinical Characteristics of Multiple Malignancies in Patients with Lung Cancer - Laura S Park
• The relationship between lower-limb lymphoedema and anxiety, depression, quality of life and overall survival post-gynaecological cancer - Melanie L Plinsinga
• Senescence-based AI Predicts Risk of Malignancy in Biopsy Images of Benign Breast Disease - Tom Rohan
• Cardioprotective Medications and the Incidence of Cardiovascular Events in Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis - Justin Smith
• Long-acting, progestin-based contraceptives and risk of breast, gynaecological and other cancers - Karen Tuesley
• Association of the G8 Score and commencing systemic treatment in older adults with cancer in an Australian Regional Cancer Centre - Paul Viray
• Burden of rare cancers in Gangwon-do, Korea - Young-Joo Won

• Exploring the Impact of Radiation Therapy Education Sessions on the Support, Information Needs and Concerns of First Nations peoples with cancer - Kenneth Carter and Thomas Fontes Andrade
• Outcomes from the co-design of a National Framework for Genomics in Cancer Control that privileges Aboriginal and Torres Strait Islander perspectives  - Justine Clark
• Current and future strategies in addressing the Unmet Need of Regional/Rural Early Phase Clinical Trials Access in Australia - Jordan E Cohen
• Increasing recruitment of CALD population to MRI Clinical Trials in Radiation Oncology - Robba Rai
• Examining the long-term financial toxicity of survivorship care for childhood brain cancer - Jordana McLoone
• Enhancing Information Equity: Sustainable Production of Patient-Comprehensible Trial Information Using Large Language Models with Expert Supervision – Preliminary Findings - Minh Tran

• Access Programs and the evolving role of the Pharmacist - Anna SHI
• Triple Negative Breast Ca- A Therapeutic Update and Case Study presentation - Nicole Pringle
• Drug Repurposing in Cancer Care - Nikola A Bowden
• New Opportunities in healthcare economics - Dean Ho

• Promoting physical activity in practice: more than just guidelines - Brigid Lynch
• Practical strategies for discussing diet and nutrition and referring to support - Lizzy Johnston
• Smoking Cessation - Henry Marshall
• Cardiovascular Health after Cancer Treatment - Susan Dent

Followed by panel discussion and Q&A

• Improving equity and quality cancer care through meaningful inclusion in research: Co-design with priority and under-served cancer populations - Rebekah Laidsaar-Powell
• Co-designing information resources with Adolescents and Young Adults (AYAs) with Cancer: addressing unmet needs and supporting uptake and accessibility - Joanna Fardell
• Using co-design with family carers of people with cancer: Focusing on meeting the unique needs of this often overlooked cancer population - Rebekah Laidsaar-Powell
• Navigating cross cultural communication in co-design - Reema Harrison
• Codesigning with People with Intellectual Disability - Bronwyn Newman
• A state-of-the-art literature review of how experience is represented in published empirical studies. Implications for codesign in cancer research and practice - Emilie Francis-Auton

• Evaluation of a co-designed culturally adapted supportive care program for Chinese-, Vietnamese- and Arabic-speaking women with cancer - Carolyn Ee
• Reducing preventable emergency visits: Results from the Oncology Nurse Practitioner-led Rapid Access Clinic (RACE) service at a tertiary regional cancer centre            - Cassandra Mazza
• ‘Engage’: A novel distance-delivered intervention to support childhood cancer survivorship care - Jordana McLoone
• The CARE PLUS Implementation Toolkit: A set of resources to guide successful implementation of early palliative care in advanced cancer care - Jennifer Philip
• Healthcare Costs for Patients with Head and Neck Cancer in Australia: A Population Data Linkage Study - Justin Smith
• Oncology antimicrobial stewardship: safe intravenous-to-oral switch and antimicrobial optimisation (OASSIS) - Karen F Urbancic

• Quantifying the diagnosis and survival of early onset bowel cancer among First Nations peoples in Queensland, Australia - Tsegaw Amare Baykeda
• Australian Aboriginal and Torres Strait Islander females and survival from breast cancer - Alice RT Bergin
• Piloting First Nations Cancer Navigators in Queensland Hospitals     - Gail Garvey
• Aboriginal and Torres Strait Islander peoples’ views and perceptions of pathways to pain management and early palliative care for people with pancreatic cancer   - Gail Garvey
• “Helping my mob” – embedding a First Nations research coordinator to improve First Nations engagement and recruitment - Mettassa Zaro and Amy Brown
• Implementing a First Nations Cancer Coordinator to Improve Cancer Outcomes and Enhance Cultural Safety for the Aboriginal and Torres Strait Islander Community in Victoria - Marissa Mulcahy

Join us at the session to discuss cancer treatments and cancer treatment-related skin toxicities, patient clinical case discussion on the management and treatment of these skin toxicities and practical tips (including dermatological) for managing skin side effects induced by cancer treatments to support patients and their cancer journey.